



Advancing Nanomedicine: Next-Generation Drug Delivery for Cancer and Regenerative Therapy

Guest Editors:

Dr. Yifan Ma

Division of Radiation Oncology,
The University of Texas MD
Anderson Cancer Center,
Houston, TX 77030, USA

Dr. Sijin Wu

Wisdom Lake Academy of
Pharmacy, Xi'an Jiaotong-
Liverpool University, Suzhou
215000, China

Deadline for manuscript
submissions:

closed (31 May 2024)

Message from the Guest Editors

Recent advances in nanomedicines, including various nanoplatforms, explorations of new molecules, and the design of targeted and personalized strategies, have made major contributions to transforming current therapeutic paradigms in improving drug delivery efficiency for cancer treatment and regeneration. This Special Issue is dedicated to the development of new delivery platforms (e.g., lipid-based nanoparticle (LNP), extracellular vesicles (EVs), polymeric nanoparticles, etc.), advanced biopharmaceutical formulations, tissue-targeted delivery, and novel routes of administration, all with the aim of optimizing drug delivery efficiency. Additionally, the combination of these advancements with other therapies or tissue engineering strategies, which synergistically enhance treatment efficacy, will be highly involved. Our aim is to collect original research papers and review papers on the development of nanomedicine delivery systems and technologies that can carry active therapeutics for the treatment and regeneration of cancer and other diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPlus / SciFinder](#), [Inspec](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Contact Us

Bioengineering Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
[X@Bioeng_MDPI](https://twitter.com/Bioeng_MDPI)